Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Apr 15;81(8):e69-e71.
doi: 10.1016/j.biopsych.2016.08.039. Epub 2016 Sep 30.

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine

Panos Zanos  1 , Ruin Moaddel  2 , Patrick J Morris  3 , Irving W Wainer  4 , Edson X Albuquerque  5 , Scott M Thompson  6 , Craig J Thomas  3 , Carlos A Zarate Jr  7 , Todd D Gould  8
Affiliations
Comment

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine

Panos Zanos et al. Biol Psychiatry. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures

All other authors report no biomedical financial interests or potential conflicts of interest.

Comment in

Comment on

  • NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD. Zanos P, et al. Nature. 2016 May 26;533(7604):481-6. doi: 10.1038/nature17998. Epub 2016 May 4. Nature. 2016. PMID: 27144355 Free PMC article.
  • Antidepressant Actions of Ketamine Versus Hydroxynorketamine.
    Collingridge GL, Lee Y, Bortolotto ZA, Kang H, Lodge D. Collingridge GL, et al. Biol Psychiatry. 2017 Apr 15;81(8):e65-e67. doi: 10.1016/j.biopsych.2016.06.029. Epub 2016 Sep 28. Biol Psychiatry. 2017. PMID: 27817845 No abstract available.

References

    1. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486. - PMC - PubMed
    1. Zarate CA, Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331–338. - PMC - PubMed
    1. Collingridge G, Lee Y, Bortolotto Z, Kang H, Lodge D. Antidepressant actions of ketamine versus hydroxynorketamine [published online ahead of print] Biol Psychiatry. 2016 - PubMed
    1. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80:424–431. - PubMed
    1. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864. - PubMed

LinkOut - more resources